Integrated analysis of diverse genomic variants for the profiling of myeloid and lymphoid neoplasms by targeted hybrid capture next-generation sequencing

This aim of this study was to explore whether a next-generation sequencing (NGS) assay could deliver a comprehensive approach for the identification of multiple types of genomic drivers. To do this the laboratory utilised a SureSeq myPanel™ Custom NGS Panel.

The results of this study evidence that by using a targeted, custom NGS panel the laboratory was able to deliver:

• Diagnostic, prognostic and therapeutic value
• Efficiency improvements
• Increased fiscal responsibility